R&D Tax Incentive
Orthocell receives $2,394,397 to fund their Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals and to advance the development and commercialisation of Ortho-ATI®.
Orthocell receives $2,394,397 to fund their Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals and to advance the development and commercialisation of Ortho-ATI®.
Funding is available to support multicultural community groups to undertake upgrades to community facilities.
A program to help reduce importing costs for Australian manufacturers of eligible goods.